Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEM2: Methotrexate for Refractory Hand Osteoarthritis
2022-502362-24-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in erosive hand osteoarthritis (EHOA) comparing Methotrexate with Placebo (2 arms). Primary endpoint: Structural damage progression by Verbruggen-Veys score. Planned start Jun 2026; status: authorised.
02
Drugs
methotrexate
03
Conditions
erosive hand osteoarthritis (EHOA)
Beyond the preview
Go deeper on 2022-502362-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502362-24-00.